Zydus Lifesciences’ shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, making it eligible for UN agency procurement.
Zydus Lifesciences’ shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, making it eligible for UN agency procurement.